You are here: Industry Insights > Pulmonary Fibrosis

News List

ISMMS, Boehringer Ingelheim to test nintedanib for treating pulmonary fibrosis post-COVID-19 infectio expresspharma
November 23, 2020
The primary endpoint of the study is percent change in forced vital capacity, a measurement of lung function, compared to baseline over six months.
Glenmark launches NINDANIB (nintedanib) for pulmonary fibrosis in India expresspharma
October 16, 2020
Two clinical trials are being rolled out to study the efficacy and safety of Nintedanib as a treatment of SARS-COV2 induced pulmonary fibrosis in moderate to severe COVID-19 patients.
EC approves new indication for Boehringer’s nintedanib in pulmonary fibrosis pharmaceutical-business-review
July 17, 2020
Boehringer Ingelheim has secured approval for a new indication of nintedanib to treat adults with other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype beyond idiopathic pulmonary fibrosis (IPF).
EmphyCorp FDA Submission for Rx New Non-Steroidal Nasal Spray for Pulmonary Fibrosis americanpharmaceuticalreview
August 16, 2019
mphyCorp announced the completion of a clinical trial to define medical endpoints as requested by the FDA for the NDA marketing application in patients with Pulmonary Fibrosis, under its Orphan Drug Designations for ...
Lung-on-a-chip simulates pulmonary fibrosis europeanpharmaceuticalreview
May 31, 2018
New biotech could reduce time and cost of developing medicine for deadly lung disease…
Sold-Out Broadway Belts For PFF! Raises Record-Breaking $350,000 For Fight Against Pulmonary Fibrosi biospace
March 21, 2018
The Pulmonary Fibrosis Foundation (PFF) announced that its annual Broadway Belts for PFF! raised a record-breaking $350,000, bringing its eight-year fundraising total to nearly $1.2 million.